RxDoctor Payments Data

Heather McDowell

Nurse Practitioner · Springfield, OHNPI 1790230639

Payments from drug & device makers

$2,087in general payments, 2019–2025

Across 112 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$758
  • Boston Scientific$338
  • Biotronik NRO, Inc.$215
  • Amgen$148
  • Vertex$128
  • Tersera Therapeutics LLC$105
  • plus $397 from 12 others

What the payments were for

  • Food & beverage$2,087100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,087 in reported general payments places this provider in the 90th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$43,158
Medicare patients
114
Services billed
471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate92$47,532
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen914$22,084
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen774$15,710
MovantikNaloxegol Oxalate32$12,370
Gabapentin720$6,540
Lidocaine61$5,988
Pregabalin194$5,551
SymproicNaldemedine Tosylate11$5,214
Oxycodone Hcl329$5,181
Tizanidine Hcl582$4,906
Morphine Sulfate ErMorphine Sulfate94$1,810
Celecoxib34$1,750
Fentanyl23$1,555
Diclofenac Sodium78$1,158
Naloxone Hcl18$1,062

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$758$47,53292 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Springfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →